Clairity Breast becomes the first FDA-authorized AI software to predict five-year breast cancer risk using routine mammography images.
Key Details
- 1FDA grants de novo authorization to Clairity Breast, developed by Boston-based Clairity.
- 2The AI tool analyzes mammogram images for subtle features correlated with future cancer risk.
- 3Unlike traditional models, Clairity Breast does not require age or genetic data.
- 4The system was trained on millions of mammogram images linked to five-year outcomes.
- 5Clairity Breast delivers validated risk scores to radiologists through standard clinical systems.
- 6Commercial launch is targeted for the end of 2025.
Why It Matters
This breakthrough FDA authorization marks a new era in preventive oncology by enabling earlier risk identification using only imaging, potentially improving precision prevention and patient outcomes in breast cancer care.
Source
Radiology Business
Related News
•Radiology Business
Rayus Radiology Launches $40 AI Mammography Screenings in Washington
Rayus Radiology is introducing a $40 AI-enhanced mammography add-on service at clinics in Washington state.
•AuntMinnie
AI-CAD Demonstrates High Sensitivity in Breast Cancer Screening
A large study found that AI-based computer-aided detection (AI-CAD) can improve breast cancer detection and support radiologists in screening mammography.
•AuntMinnie
AI Tool Mirai Shows Robust Performance for Interval Breast Cancer Detection
The Mirai AI model significantly improves detection of interval breast cancers in negative screening mammograms.